Direct compression feasibility for (-)-Corey lactone 4-phenylbenzoate alcohol is assessed only after the API lot passes a particle size distribution screen by laser diffraction according to USP <429> and a powder flow screen using a ring shear cell, because both the 4-phenylbenzoate ester and the fused γ-lactone are susceptible to hydrolytic ring opening under alkaline and high-humidity conditions. Raw API is first milled using a spiral jet mill operated with nitrogen at 0.5–2.0 bar grinding pressure and 1.5–3.0 bar injector pressure, with a target d90 selected by dissolution risk assessment; for poorly water-soluble crystalline APIs, a d90 below 20 µm is generally required when the dissolution rate rather than the solubility limit controls release, though published data for this specific compound are limited. The milled API is blended with microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, and colloidal silicon dioxide in a bin blender at 10 rpm for 20 min, with an intensifier bar paused to avoid local thermal excursions. Because both ester and lactone moieties undergo base-catalyzed hydrolysis, the direct compression formula is buffered with anhydrous citric acid to maintain a micro-pH below 5.0 in the adsorbed moisture layer; amine-based excipients such as meglumine or tris are excluded because they raise the adsorbed moisture layer pH and accelerate saponification. Lubricant is limited to sodium stearyl fumarate at 0.5–1.0 wt% instead of magnesium stearate when a 12-station rotary press equipped with B-tooling and paddle force feeder is run at 40–60 rpm. In-process controls include table weight at ±2% of target, hardness tested to 7–12 kp, friability not more than 1.0% per USP <1216>, and disintegration tested in 900 mL of 0.05 M phosphate buffer at 37 °C; acceptance is aligned to USP <701> with no residual core exceeding 2 mm at 15 min. Blend uniformity is checked at 10× and 100× dilution levels and must meet an acceptance value ≤ 15.0 for 10 units by USP <905>. If acicular crystal habit is observed by polarized light microscopy after jet milling, direct compression is not selected as the primary route because needle-like particles increase capping risk at compression forces above 8 kN; instead, dry granulation is evaluated.

Does Roller Compaction Preserve the Chiral Ester-Lactone Stereochemistry During Binder-Free Dry Granulation?

Roller compaction is used when direct compression shows capping or poor flow at API loadings above 20 wt%; the process itself is binder-free because the API is pre-blended with microcrystalline cellulose, lactose monohydrate, and croscarmellose sodium, then passed through a roller compactor with side seal, 250 mm roll diameter, 50 mm roll width, and knurled roll surface. Hydraulic pressure is set between 60 bar and 120 bar, roll gap is held at 1.5–2.0 mm, and roll speed is limited to 4–8 rpm to avoid local frictional heating; the resulting ribbon solid fraction is determined by helium pycnometry per USP <699> and maintained between 0.55 and 0.70 so that downstream granules are dense enough to recompress but not so dense that dissolution rate is retarded by loss of internal porosity. Ribbons are milled through a rotary granulator equipped with a 0.8 mm rasping screen at 60 rpm, and the granule fraction between 125 µm and 850 µm is selected for tableting; fines below 125 µm are recycled at a ratio not exceeding 25% of the total blend to prevent segregation and content uniformity drift. Because the API contains a chiral center embedded in a lactone ring, pooled granule samples are tested for enantiomeric purity by chiral HPLC with a polysaccharide-based stationary phase and for related substances by a stability-indicating reversed-phase HPLC method; any increase in the sum of specified and unspecified degradation products beyond 0.2% triggers a process hold and equipment inspection. Final tablets are compressed on a rotary press with B-tooling at 10–18 kN compression force, and the tablets are tested for hardness, friability per USP <1216>, and dissolution in 900 mL of pH 4.5 acetate buffer containing 0.5% sodium lauryl sulfate using USP <711> apparatus II at 50 rpm. The dry granulation route is preferred over wet granulation for this ester-lactone when ambient relative humidity exceeds 60% because it eliminates water addition and reduces the need for high-temperature drying. Published data for this specific chemical configuration are limited; operational limits must be confirmed on the production-scale roller compactor rather than assumed from placebo runs.

Wet Granulation Solvent Selection and Residual Water Limits for an Ester-Lactone API

Wet granulation is selected only when particle size reduction by jet milling fails to deliver acceptable dissolution, and the granulation solvent must be chosen to avoid both ester saponification and lactone ring opening. Aqueous granulation with povidone K30 is not used as the default because the pH of a typical aqueous starch paste can drift above 6.0, and base-catalyzed hydrolysis of the 4-phenylbenzoate ester becomes detectable in forced degradation studies at pH values above 6.5 when temperature exceeds 40 °C; published data for this specific derivative are limited, but the structural liability of the phenylbenzoate ester and γ-lactone is well established. Non-aqueous granulation with anhydrous ethanol or isopropanol is therefore evaluated, with povidone K30 or copovidone dissolved at 5–10% w/w as binder solution. The granulation endpoint is controlled by amperage or impeller torque on a high-shear granulator; for a 10 L bowl, the endpoint is defined as a power consumption plateau of 60–75% of the calibrated maximum after 2–4 min of wet massing. The wet granules are dried in a fluid bed dryer with inlet air temperature not exceeding 45 °C to avoid thermal degradation of the ester-lactone, and the product temperature is monitored with a probe not exceeding 38 °C. Residual solvent must meet ICH Q3C Class 3 limits: ethanol and isopropanol are each controlled at ≤ 0.5% (5000 ppm) by headspace gas chromatography per USP <467>, and residual water is measured by Karl Fischer titration per USP <921> Method Ia with a limit of ≤ 2.0% for granules intended for tablet compression. If water is used as a granulation fluid at any level, the final granule water activity is measured and the formulation is buffered with anhydrous citric acid to keep the steady-state moisture layer pH below 5.0. Granules are milled through a conical mill with a 1.0 mm screen and mixed with extragranular disintegrant and lubricant; the final blend is compressed to tablets with hardness and friability limits described for the direct compression route. Tablet cores containing wet granulated material are tested for related substances at release and at 40 °C / 75% RH in long-term stability chambers to detect any hydrolytic degradation caused by residual water. Aqueous granulation may be considered only if a forced degradation study demonstrates that the API loss is below 0.5% after 24 h in a slurry at 25 °C; otherwise, the process is rejected as incompatible with an ester-lactone API.

Low-dose encapsulation of (-)-Corey lactone 4-phenylbenzoate alcohol on an intermittent-motion capsule filler using dosator technology requires a pre-blend prepared by geometric dilution in a V-blender at 12 rpm for 25 min; the first dilution is typically 1:10 API to lactose monohydrate, followed by a second 1:10 dilution, and a final addition of pregelatinized starch and sodium starch glycolate to give a final fill weight between 150 mg and 350 mg for size 1 or size 0 capsules. Fill weight variation is controlled to ±3% for capsules below 300 mg net weight, and the filled capsules are sampled at 15-min intervals for weight, lock length, and visual defects; content uniformity must meet USP <905> with an acceptance value ≤ 15.0 for 10 units at release and end of shelf life. Dissolution testing is carried out in USP <711> apparatus II at 50 rpm in 900 mL of 0.1 N HCl with 0.5% sodium lauryl sulfate if the aqueous solubility of the API is below 0.1 mg/mL; surfactant concentration is justified by sink condition data and not increased solely to force release. Capsule shell selection avoids gelatin at high moisture because the ester-lactone may hydrolyze at the capsule interface when shell moisture content exceeds 13%; HPMC capsules with a shell moisture specified at 3–7% are preferred for humidity-sensitive fill formulations, and the empty shell supplier's certificate must include water activity and microbial limits per USP <61> and USP <62>. If modified-release pellets are needed, extrusion-spheronization using microcrystalline cellulose and a non-aqueous binder solution is preferred over aqueous layering; pellet cores are seal-coated with ethylcellulose or Eudragit L100-55 at 5–10% weight gain, and the coated pellets are tested for gastric resistance in 0.1 N HCl for 2 h followed by pH 6.8 phosphate buffer. Process scale-up uses the same dosator nozzle diameter and compression ratio to maintain plug density; changes in fill weight are achieved by adjusting powder bed height rather than compression thickness. If the capsule filling room relative humidity exceeds 60%, the API is pre-dried in a vacuum tray dryer at 35–40 °C for 6–8 h and the dried material is not held for more than 4 h before filling.

When Terminal Sterilization Is Rejected for an Injectable Ester-Lactone Due to Hydrolysis Risk

Aseptic processing with sterile filtration is selected when terminal sterilization is rejected on the basis of hydrolytic degradation of the 4-phenylbenzoate ester and lactone ring in steam at 121 °C. The injectable formulation is compounded in a ISO 14644-1 Class 5 controlled environment using a vehicle selected from solubility screening; because the API is hydrophobic, a non-aqueous or co-solvent vehicle containing PEG 400, propylene glycol, and a small amount of polysorbate 80 may be used, but the final formulation pH, if an aqueous phase is present, is adjusted with citrate buffer to 5.0–6.0. The bulk solution is filtered through a 0.22 µm sterilizing-grade PVDF or PES membrane filter validated for bacterial retention per ASTM F838-20; filter compatibility is checked by measuring extractables, and the maximum filtration pressure is limited to 1.5 bar to avoid filter rupture. The filled vials are stoppered under Grade A and subjected to 100% visual inspection per USP <790>; subvisible particulate matter is tested by light obscuration per USP <788> with acceptance criteria dependent on the labeled volume. Bacterial endotoxins are determined by kinetic chromogenic LAL per USP <85>; the limit is calculated from the maximum bolus dose, with a default of 5 EU/kg for non-intrathecal parenterals unless a stricter product-specific limit is assigned. Residual solvents from the synthesis and formulation must comply with ICH Q3C; if dichloromethane was used in the final API recrystallization, the limit is 600 ppm, and if methanol was used the limit is 3000 ppm, both determined by headspace GC per USP <467>. Elemental impurities are controlled per ICH Q3D using ICP-MS after closed-vessel microwave digestion; if a palladium or nickel catalyst was used, the parenteral PDE limits for Pd and Ni are 10 µg/day and 20 µg/day, respectively. Because the ester-lactone is not water-soluble, a clear aqueous solution may not be achievable without a co-solvent or surfactant; if the solubility remains below 0.1 mg/mL, lyophilization of a co-solvent system or a nanosuspension is evaluated.

Residual Moisture in the Freeze-Dried Cake Must Stay Below the Hydrolysis Threshold Established by Karl Fischer Titration

Lyophilization of a parenteral co-solvent or aqueous suspension requires a freeze-drying microscopy study to identify the collapse temperature before cycle design, because microcollapse of the cake alters reconstitution time and can expose the ester-lactone to localized high-moisture domains. For a typical formulation with mannitol as crystallizing bulking agent and trehalose or sucrose as amorphous stabilizer at 5–10% w/v, the solution is frozen to -45 °C at 0.5 °C/min, annealed at -10 °C for 2 h to crystallize mannitol, and dried with a primary drying shelf temperature of -30 °C to -20 °C and chamber pressure of 60–100 mTorr. Endpoint is determined by a Pirani gauge and capacitance manometer differential; the Pirani signal rises sharply when water vapor flux from the product ceases. Secondary drying is run at 25–35 °C for 6–12 h until the cake reaches a residual moisture content below 1.0% by Karl Fischer titration per USP <921>. The final vials are stoppered under dry nitrogen to avoid rehydration of the amorphous phase, and the headspace oxygen is controlled below 2.0%. Reconstitution time is specified as ≤ 2 min with 5 mL of water for injection; residual visible particulates after reconstitution must meet USP <790>, and subvisible particulates must meet USP <788>. Because the active molecule contains a phenylbenzoate ester and a γ-lactone, the lyophilized cake is tested for related substances immediately after reconstitution and after 24 h at 25 °C in the reconstituted vehicle; any increase above 0.2% total degradation products is considered a formulation failure. The lyophilization cycle for this specific derivative has limited published data, therefore pilot freeze-drying with thermocouple mapping and controlled nucleation is required before commercial scale-up; cycles that work for simple amorphous sugars cannot be transferred directly to an ester-lactone API without confirming residual moisture and degradation product levels.